[go: up one dir, main page]

DK3369435T3 - Sammensætning til behandling af inflammatorisk ledsygdom - Google Patents

Sammensætning til behandling af inflammatorisk ledsygdom Download PDF

Info

Publication number
DK3369435T3
DK3369435T3 DK18167083T DK18167083T DK3369435T3 DK 3369435 T3 DK3369435 T3 DK 3369435T3 DK 18167083 T DK18167083 T DK 18167083T DK 18167083 T DK18167083 T DK 18167083T DK 3369435 T3 DK3369435 T3 DK 3369435T3
Authority
DK
Denmark
Prior art keywords
treatment
composition
inflammatory disease
inflammatory
disease
Prior art date
Application number
DK18167083T
Other languages
English (en)
Inventor
Robert Landry
Raymond A Chavez
Linda R Watkins
Original Assignee
Xalud Therapeutics Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xalud Therapeutics Inc, Univ Colorado Regents filed Critical Xalud Therapeutics Inc
Application granted granted Critical
Publication of DK3369435T3 publication Critical patent/DK3369435T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18167083T 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom DK3369435T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361847851P 2013-07-18 2013-07-18
EP14826787.5A EP3021873B8 (en) 2013-07-18 2014-07-17 Composition for the treatment of inflammatory joint disease

Publications (1)

Publication Number Publication Date
DK3369435T3 true DK3369435T3 (da) 2019-11-25

Family

ID=52346725

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14826787.5T DK3021873T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom
DK18167083T DK3369435T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14826787.5T DK3021873T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom

Country Status (15)

Country Link
US (4) US10512672B2 (da)
EP (2) EP3369435B1 (da)
JP (4) JP2016525522A (da)
CY (2) CY1120946T1 (da)
DK (2) DK3021873T3 (da)
ES (2) ES2760902T3 (da)
HR (2) HRP20181913T1 (da)
HU (2) HUE042463T2 (da)
LT (2) LT3021873T (da)
PL (2) PL3021873T3 (da)
PT (2) PT3021873T (da)
RS (2) RS57974B1 (da)
SI (2) SI3021873T1 (da)
SM (2) SMT201900657T1 (da)
WO (1) WO2015009955A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181913T1 (hr) 2013-07-18 2019-01-11 Xalud Therapeutics, Inc. Sastav za liječenje upale bolesti zglobova
EP3445849B1 (en) * 2016-04-22 2024-06-05 Xalud Therapeutics, Inc. Methods and compositions to enhance the anti-inflammatory effects of interleukin 10
TW202216743A (zh) * 2020-06-26 2022-05-01 美商安進公司 Ｉｌ－１０突變蛋白及其融合蛋白
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
KR0170037B1 (ko) 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
US5922018A (en) 1992-12-21 1999-07-13 Artann Corporation Method for using a transrectal probe to mechanically image the prostate gland
US5373317B1 (en) 1993-05-28 2000-11-21 Welch Allyn Inc Control and display section for borescope or endoscope
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6159937A (en) 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5716804A (en) 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
AU5689898A (en) 1996-12-05 1998-06-29 University Of Florida Il-10 and tgf-beta for treating autoimmune disease
US6201880B1 (en) 1996-12-31 2001-03-13 Electro-Optical Sciences Method and apparatus for electronically imaging a tooth through transillumination by light
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999047157A1 (en) 1998-03-17 1999-09-23 Schering Corporation Use of il-10 to treat major depressive disorder
EP1254961A1 (en) 1998-05-06 2002-11-06 Transgene S.A. Improvments in gene therapy using compositions comprising a polynucleotide and interleukin-10
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6165754A (en) 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
US20050129669A1 (en) 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
CA2407074A1 (en) 2000-04-21 2001-11-01 Jukka Hartikka Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
AU2002217929A1 (en) 2000-11-28 2002-06-11 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
AU2002233239B2 (en) * 2000-12-13 2006-05-11 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002087594A1 (en) 2001-04-30 2002-11-07 The Regents Of The University Of California Non-viral vesicle vector for cardiac specific gene delivery
JP4578735B2 (ja) 2001-08-28 2010-11-10 オリンパス株式会社 内視鏡画像ファイリングシステム
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
JP2003146909A (ja) 2001-11-07 2003-05-21 Children's Hospital Of Philadelphia 治療用ポリペプチドに対する免疫寛容の誘導
AU2003209226A1 (en) 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
AU2003221745A1 (en) 2002-04-19 2003-11-03 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20040186357A1 (en) 2002-08-20 2004-09-23 Welch Allyn, Inc. Diagnostic instrument workstation
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US20040142893A1 (en) 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7530946B2 (en) 2003-08-15 2009-05-12 Scimed Life Systems, Inc. Compact endoscope
US7276486B2 (en) 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
KR20070058441A (ko) * 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
US20060073119A1 (en) 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
US20100028296A1 (en) 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
DE602006011311D1 (de) * 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
WO2007016501A2 (en) 2005-08-01 2007-02-08 The University Of Chicago Compositions and method for brain specific targeted delivery of therapeutic agents
WO2008109806A2 (en) 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
US7846428B2 (en) 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
JP5932830B2 (ja) * 2010-12-15 2016-06-08 オラテック セラピューティクス リミティド ライアビリティ カンパニー 炎症及び疼痛を処置するための３‐メタンスルホニルプロピオニトリル
US20150044281A1 (en) 2012-01-06 2015-02-12 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
HRP20181913T1 (hr) 2013-07-18 2019-01-11 Xalud Therapeutics, Inc. Sastav za liječenje upale bolesti zglobova
EP3445849B1 (en) 2016-04-22 2024-06-05 Xalud Therapeutics, Inc. Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

Also Published As

Publication number Publication date
LT3021873T (lt) 2018-11-26
ES2700826T3 (es) 2019-02-19
HUE042463T2 (hu) 2019-07-29
EP3021873A1 (en) 2016-05-25
DK3021873T3 (da) 2018-12-17
US20220313785A1 (en) 2022-10-06
US20230158114A1 (en) 2023-05-25
ES2760902T3 (es) 2020-05-18
RS59735B1 (sr) 2020-02-28
JP2016525522A (ja) 2016-08-25
US10512672B2 (en) 2019-12-24
RS57974B1 (sr) 2019-01-31
JP7066669B2 (ja) 2022-05-13
CY1122673T1 (el) 2021-03-12
PL3369435T3 (pl) 2020-04-30
HUE046944T2 (hu) 2020-03-30
JP2025023096A (ja) 2025-02-14
EP3369435A1 (en) 2018-09-05
SMT201800655T1 (it) 2019-01-11
HRP20181913T1 (hr) 2019-01-11
PT3369435T (pt) 2019-12-05
SI3369435T1 (sl) 2020-03-31
US20200093892A1 (en) 2020-03-26
SI3021873T1 (sl) 2018-12-31
PT3021873T (pt) 2018-12-10
US20160235816A1 (en) 2016-08-18
PL3021873T3 (pl) 2019-01-31
JP2022031682A (ja) 2022-02-22
WO2015009955A1 (en) 2015-01-22
EP3021873A4 (en) 2016-11-30
HRP20192043T1 (hr) 2020-02-07
SMT201900657T1 (it) 2020-01-14
LT3369435T (lt) 2020-01-10
CY1120946T1 (el) 2019-12-11
EP3021873B8 (en) 2018-10-24
EP3369435B1 (en) 2019-09-04
JP2020037562A (ja) 2020-03-12
EP3021873B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
CY2021007I1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK2968208T3 (da) Behandling af kataplexi
DK2984166T3 (da) Sammensætninger til behandling af mpsi
PT3030262T (pt) Composição farmacêutica de associação
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
EP2889350A4 (en) ADHESIVE COMPOSITION
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3021838T3 (da) Behandling af fedme
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3027750T3 (da) Biokatalytisk sammensætning
PT2953948T (pt) Antagonistas de integrina fluorada
PT3071638T (pt) Composição de cianoacrilato
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3021839T3 (da) Sammensætninger for behandling af fibrose
LT3007726T (lt) Tautopatijos gydymo būdai
DK3511004T3 (da) Kombineret præparat til behandling af cancer
EP2945942A4 (en) Voriconazole IMMUNOASSAY